Navigation Links
Syndax Pharmaceuticals Appoints Arlene Morris as CEO
Date:4/18/2012

WALTHAM, Mass., April 18, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies, announced the appointment of Arlene M. Morris as chief executive officer.  Joanna Horobin, MD will serve as president. 

"Syndax is leading the field of epigenetics—a novel way to control gene regulation—to address unmet needs in cancer due to the problem of resistance," said Dennis Podlesak, chairman of the Syndax board of directors. "With the positive phase 2 randomized, placebo-controlled data and the addition of Arlene Morris to our impressive leadership team, Syndax is well positioned to successfully complete the final phase of clinical development to achieve our goal of providing a new treatment option for women with metastatic breast cancer."

During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Omontys®), a strategic collaboration with Takeda and an Initial Public Offering. Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counseled biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotechnology company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development. Ms. Morris received her bachelor's degree in biology and chemistry from Carlow College. In addition to Syndax Ms. Morris serves on the board of directors of Neovacs and MediciNova.

"After working with Syndax as a director over the past nine months
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
2. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
3. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
4. Syndax Pharmaceuticals to Present at BIO Investor Forum
5. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CELEBRATION, Fla. , Aug. 27, 2015 ... announced that a patient,s eyes—and life—were saved by doctors ... , working with NNFF, NovaBay Pharmaceuticals and Dr. ... Wound Care Center at Seton Medical Center in ... The successful treatment used a breakthrough approach, pioneered by ...
(Date:8/27/2015)... HUYA Bioscience International (HUYA) today announced the sponsorship ... of HTLV-1, held this week at the University of ... Society is to promote research on HTLV-1 and HTLV-1-associated ... and research related to these fields to advance science, ... proud to support this prestigious conference," said Mireille ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... product choices to a manageable shortlist of bench and floor scales and terminals. ... fit best with the customer’s industry and application. , Side-by-side product comparisons ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader ... laboratory is to open in Manhattan, Kansas in early October, 2015. The location ... of research and development through collaboration with researchers from Kansas State University’s College ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... Inc., a development stage biopharmaceutical company, announced that ... Puma,s investigational drug PB272 (neratinib) were presented at ... that is currently taking place in San Antonio, ... Safety and Efficacy of Neratinib ...
... Rabindranauth, MD, a heart surgeon at Gundersen Lutheran ... is using an exciting technique, called minimally invasive coronary ... MICS, a very small three-inch cut is made between the ribs ... is needed with traditional open heart surgery. This means less ...
... Life Length®, the world,s leading telomere testing and services company, ... Boca Raton, Florida to offer its test nationwide.  The partnership ... be forwarded to Life Length,s lab in Europe for analysis. ... are delighted to partner with ADL. This is a major ...
Cached Biology Technology:Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 2Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 3Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 4Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 5Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 6Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2Life Length Telomere Test Available Nationwide 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/18/2015)... DUBLIN , Aug. 17, 2015 ... the addition of the "Global Biometric Authentication ... Application - Estimation & Forecast, 2015-2020" report ... biometric authentication and identification systems market is expected ... from 2015 to 2020 and generate over $25 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... studies show promise for significantly reducing vascular aging by ... dysfunction and cell death. The related report by ... aging," appears in the January issue of The American ... blood pressure, heart attack and stroke, occur naturally, even ...
... named Charlotte, but they are weaving a new chapter ... University have led to the discovery of 25 new ... the first time in Texas. , In research sponsored ... a master's degree, has been studying ground spider diversity, ...
... How many grizzly bears should call Yellowstone home" ... Conservationist biologists grapple with the task of setting ... protect ?a decision steeped in politics, emotion, and sometimes, ... journal Bioscience, the New York-based Wildlife Conservation Society (WCS) ...
Cached Biology News:A new jump start for aging blood vessels 2Ground spider diversity studied in research project 2Save the whales? Sure, but how many? 2
... DNA-binding protein(DBP). Protein size: ... NP_001343 ELISA titre using peptide based ... for Western Blot: 1.0g/ml in ... HRP conjugated anti-Rabbit IgG should be diluted ...
Porcine Serum US Origin 6 Months or Older...
... DCTD_HUMAN GI Number: 4503277 ... 20016 Description: FUNCTION: Supplies the ... ACTIVITY: dCMP + H 2 O ... SUBUNIT: Homohexamer. SIMILARITY: Belongs to the ...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Biology Products: